Chen J, Barrett L, Lin Z, [et al., including Kendrick S]. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. Journal of cellular and molecular medicine. 2022. PMID: 35318805.
Chen J, Dai L, Kendrick S, [et al.]. The anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesviruses Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrobial agents and chemotherapy. 2022:aac0239521. PMID: 35041508.
Mohan M, Kendrick S, Szabo A, [et al.]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986.
Mohan M, Szabo A, Yarlagadda N, [et al., including Kendrick S]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
Mohan M, Tackett A, Kumar M, [et al., including Kendrick S]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629.
Brown SL, Kendrick S. The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure. Pharmaceuticals (Basel, Switzerland). 2021 14(2). PMID: 33513764.
Xu YZ, Jenjaroenpun P, Wongsurawat T, [et al., including Kendrick S]. Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. NAR cancer. 2020 2(4):zcaa029. PMID: 33094287. PMCID: PMC7556405.
Shponka V, Reveles CY, Alam S, [et al., including Kendrick S]. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS (London, England). 2020 34(14):2025-2035. PMID: 32773475.
Storey AJ, Naceanceno KS, Lan RS, [et al., including Kendrick S]. ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Molecular omics. 2020. PMID: 32347222.
Chen J, Forrest J, post s, [et al., including Kendrick S]. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses. 2019 11(12). PMID: 31888174. PMCID: PMC6950054.
Maguire A, Chen X, Wisner L, [et al., including Kendrick S]. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. International journal of cancer. 2019 145(11):3078-3088. PMID: 31044434.
Kendrick S, Muranyi A, Gokhale V, [et al.]. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. Journal of medicinal chemistry. 2017 60(15):6587-6597. PMID: 28605593.
Cunin P, Penke LR, Thon JN, [et al., including Lacroix S]. Megakaryocytes compensate for Kit insufficiency in murine arthritis. The Journal of clinical investigation. 2017 127(5):1714-1724. PMID: 28375155. PMCID: PMC5409069.
Kendrick S, Rimsza LM, Scott DW, [et al.]. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Archiv : an international journal of pathology. 2017 470(1):113-117. PMID: 27888357.
Kendrick S, Kang HJ, Alam MP, [et al.]. Correction to "The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure". Journal of the American Chemical Society. 2016 138(35):11408. PMID: 27571358.
Kendrick S, Tus K, Wright G, [et al.]. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia & lymphoma. 2016 57(3):717-20. PMID: 26437080. PMCID: PMC5937932.
Li L, Pongtornpipat P, Tiutan T, [et al., including Kendrick SL]. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015 29(8):1702-12. PMID: 25882699. PMCID: PMC4526343.